All In Biotech

Investigational drug · Phase 3

Ianalumab

Also called: VAY736, VAY736 AI

Not approved by FDA. In 18 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Primary Immune Thrombocytopenia (ITP), Systemic Lupus Erythematosus, Sjogren Syndrome.

Phase 3

Last checked: Nov 20, 2026Latest source record: Nov 17, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations

Highest phase

Phase 3

Industry-sponsored trials

Phase 2 and 3 trials

18

16 still active

All registered trials

35

Any phase or sponsor naming "Ianalumab"

First trial start

2019

Feb 27, 2019

Sponsors

Lead sponsors of its Phase 2 and 3 trials.

All registered trials by phase

Every ClinicalTrials.gov drug study naming "Ianalumab", any sponsor or status.

Conditions studied

As listed on its trial records.

  • Primary Immune Thrombocytopenia (ITP)
  • Systemic Lupus Erythematosus
  • Sjogren Syndrome
  • Lupus Nephritis
  • Sjogrens Syndrome
  • Diffuse Cutaneous Systemic Sclerosis
  • Sjögren´s Disease
  • Primary Immune Thrombocytopenia
  • Sjögrens Disease
  • Rheumatoid Arthritis

Approved drugs for the same conditions: Immune thrombocytopenia · Rheumatoid arthritis · Lupus (SLE) · Hematology and blood cancers · Cardiovascular and metabolic · Immunology and inflammation · Rare and genetic disease · Kidney and urology

Largest trials

Live from ClinicalTrials.gov: studies naming "Ianalumab" as an intervention, largest first.

All trials

Newest research

PubMed records naming it or its code names, newest first.

All 45 on PubMed

Also in development for Primary Immune Thrombocytopenia (ITP)

  • HMPL-523SovleplenibPhase 32 trials

    Hutchmed · Warm Antibody Autoimmune Hemolytic Anemia, Primary Immune Thrombocytopenia (ITP)

  • STSA-1301Phase 21 trial

    Jiangsu BioJeTay Biotechnology Co., Ltd. · Primary Immune Thrombocytopenia (ITP)

Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do. More from Novartis.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.